This site is no longer operational contact Shire Pharmaceuticals for further information.
At Jerini US, we are driven by a commitment to improving the quality of life for people having rare diseases, with a primarily focus on HAE (hereditary angioedema).
We are proud to introduce JeriniCaresSM, a program that provides HAE patients and health care professionals with information on coverage, reimbursement and claims processing requirements for HAE medications. |
|
|
 |
| REGISTER NOW to gain access to areas of the website containing additional information on hereditary angioedema in the HAE Information Center.
Sign-up to receive personalized information and/or assistance regarding:
• Reimbursement assistance for HAE patients and support for health care offices
• Possibly reducing the cost of current HAE therapy
• HAE related disease information, when available
• Potential Jerini US sponsored clinical trials
• Jerini US specific marketing and/or product information, when available
|
|
|
|
5 Aug 2008
-
JeriniCares Program Launched
JeriniCares Program Launched
Morristown, NJ, August 5th, 2008 – Jerini US announced today that the company has launched its JeriniCares initiative to help patients with the treatment of acute at... View Release
|
|
|
|
| | |
Get Help With HAE
-
Third-party coverage
-
Product specific coverage
-
Therapy restrictions / limitations
-
Information on registering interest
in potential Jerini US sponsored
clinical trials
-
Prior Authorization / Statement
of Medical Necessity (SMN)
-
Insurance forms
-
Insurance coding
-
Appeals of denied claims
|
| 
Login to the JeriniCares Information Center.
|
|
|
